Clinical Trial Update: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL [Phase 1]

View source ↗

Summary

This report summarizes results from a Phase I/Ib safety and preliminary efficacy study of the PI3K-delta inhibitor TGR-1202 in combination with ibrutinib. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• TGR-1202 (umbralisib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2020-06-23